Ryntexia Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.63 M
- Revenue Growth 184.34%
- Profit Growth 13.25%
- Ebitda -1827.77%
- Net Worth 17.81%
- Total Assets 252.53%
About Ryntexia Pharma
Ryntexia Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2018 (Six years and two months 14 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.63 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Neelam Tomar and Udaya Tomar serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2018PTC110816
-
Company No.
110816
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Dec 2018
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ryntexia Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neelam Tomar
|
Director | 03-Dec-2018 | Current |
|
Udaya Tomar
|
Director | 03-Dec-2018 | Current |
Financial Performance of Ryntexia Pharma.
Ryntexia Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 184.34% increase. The company also saw a substantial improvement in profitability, with a 13.25% increase in profit. The company's net worth Soared by an impressive increase of 17.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ryntexia Pharma?
In 2019, Ryntexia Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0.63 M
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jun 2021 | Indian Overseas Bank | ₹0.45 M | Satisfied |
| 14 Aug 2020 | Indian Overseas Bank | ₹0.03 M | Satisfied |
| 30 Jul 2019 | Indian Overseas Bank | ₹0.15 M | Satisfied |
How Many Employees Work at Ryntexia Pharma?
Unlock and access historical data on people associated with Ryntexia Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ryntexia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ryntexia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.